Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma

Emma Essock-Burns, Janine M. Lupo, Soonmee Cha, Mei-Yin Polley, Nicholas A. Butowski, Susan M. Chang, Sarah J. Nelson

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

The paradigm for treating patients with glioblastoma multiforme (GBM) is shifting from a purely cytotoxic approach to one that incorporates antiangiogenic agents. These are thought to normalize the tumor vasculature and have shown improved disease management in patients with recurrent disease. How this vascular remodeling evolves during the full course of therapy for patients with newly diagnosed GBM and how it relates to radiographic response and outcome remain unclear. In this study, we examined 35 patients who were newly diagnosed with GBM using dynamic susceptibility contrast (DSC) MRI in order to identify early predictors of radiographic response to antiangiogenic therapy and to evaluate changes in perfusion parameters that may be predictive of progression. After surgical resection, patients received enzastaurin and temozolomide, both concurrent with and adjuvant to radiotherapy. Perfusion parameters, peak height (PH) and percent recovery, were calculated from the dynamic curves to assess vascular density and leakage. Sixmonth radiographic responders showed a significant improvement in percent recovery between baseline and 2 months into therapy, whereas 6-month radiographic nonresponders showed significantly increased PH between baseline and 1 month. At 2 months into therapy, percent recovery was predictive of progression-free survival. Four months prior to progression, there was a significant increase in the standard deviation of percent recovery within the tumor region. DSC perfusion imaging provides valuable information about vascular remodeling during antiangiogenic therapy, which may aid clinicians in identifying patients who will respond at the pretherapy scan and as an early indicator of response to antiangiogenic therapy.

Original languageEnglish (US)
Pages (from-to)119-131
Number of pages13
JournalNeuro-Oncology
Volume13
Issue number1
DOIs
StatePublished - Jan 1 2011
Externally publishedYes

Fingerprint

Glioblastoma
Perfusion
temozolomide
Therapeutics
Adjuvant Radiotherapy
Angiogenesis Inhibitors
Perfusion Imaging
Disease Management
Disease-Free Survival
Blood Vessels
Neoplasms

Keywords

  • Antiangiogenic therapy
  • DSC
  • Enzastaurin
  • GBM
  • MRI
  • Perfusion imaging

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Clinical Neurology

Cite this

Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma. / Essock-Burns, Emma; Lupo, Janine M.; Cha, Soonmee; Polley, Mei-Yin; Butowski, Nicholas A.; Chang, Susan M.; Nelson, Sarah J.

In: Neuro-Oncology, Vol. 13, No. 1, 01.01.2011, p. 119-131.

Research output: Contribution to journalArticle

Essock-Burns, Emma ; Lupo, Janine M. ; Cha, Soonmee ; Polley, Mei-Yin ; Butowski, Nicholas A. ; Chang, Susan M. ; Nelson, Sarah J. / Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma. In: Neuro-Oncology. 2011 ; Vol. 13, No. 1. pp. 119-131.
@article{c715a1ced8744ef194ea42f2e1364a9e,
title = "Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma",
abstract = "The paradigm for treating patients with glioblastoma multiforme (GBM) is shifting from a purely cytotoxic approach to one that incorporates antiangiogenic agents. These are thought to normalize the tumor vasculature and have shown improved disease management in patients with recurrent disease. How this vascular remodeling evolves during the full course of therapy for patients with newly diagnosed GBM and how it relates to radiographic response and outcome remain unclear. In this study, we examined 35 patients who were newly diagnosed with GBM using dynamic susceptibility contrast (DSC) MRI in order to identify early predictors of radiographic response to antiangiogenic therapy and to evaluate changes in perfusion parameters that may be predictive of progression. After surgical resection, patients received enzastaurin and temozolomide, both concurrent with and adjuvant to radiotherapy. Perfusion parameters, peak height (PH) and percent recovery, were calculated from the dynamic curves to assess vascular density and leakage. Sixmonth radiographic responders showed a significant improvement in percent recovery between baseline and 2 months into therapy, whereas 6-month radiographic nonresponders showed significantly increased PH between baseline and 1 month. At 2 months into therapy, percent recovery was predictive of progression-free survival. Four months prior to progression, there was a significant increase in the standard deviation of percent recovery within the tumor region. DSC perfusion imaging provides valuable information about vascular remodeling during antiangiogenic therapy, which may aid clinicians in identifying patients who will respond at the pretherapy scan and as an early indicator of response to antiangiogenic therapy.",
keywords = "Antiangiogenic therapy, DSC, Enzastaurin, GBM, MRI, Perfusion imaging",
author = "Emma Essock-Burns and Lupo, {Janine M.} and Soonmee Cha and Mei-Yin Polley and Butowski, {Nicholas A.} and Chang, {Susan M.} and Nelson, {Sarah J.}",
year = "2011",
month = "1",
day = "1",
doi = "10.1093/neuonc/noq143",
language = "English (US)",
volume = "13",
pages = "119--131",
journal = "Neuro-Oncology",
issn = "1522-8517",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma

AU - Essock-Burns, Emma

AU - Lupo, Janine M.

AU - Cha, Soonmee

AU - Polley, Mei-Yin

AU - Butowski, Nicholas A.

AU - Chang, Susan M.

AU - Nelson, Sarah J.

PY - 2011/1/1

Y1 - 2011/1/1

N2 - The paradigm for treating patients with glioblastoma multiforme (GBM) is shifting from a purely cytotoxic approach to one that incorporates antiangiogenic agents. These are thought to normalize the tumor vasculature and have shown improved disease management in patients with recurrent disease. How this vascular remodeling evolves during the full course of therapy for patients with newly diagnosed GBM and how it relates to radiographic response and outcome remain unclear. In this study, we examined 35 patients who were newly diagnosed with GBM using dynamic susceptibility contrast (DSC) MRI in order to identify early predictors of radiographic response to antiangiogenic therapy and to evaluate changes in perfusion parameters that may be predictive of progression. After surgical resection, patients received enzastaurin and temozolomide, both concurrent with and adjuvant to radiotherapy. Perfusion parameters, peak height (PH) and percent recovery, were calculated from the dynamic curves to assess vascular density and leakage. Sixmonth radiographic responders showed a significant improvement in percent recovery between baseline and 2 months into therapy, whereas 6-month radiographic nonresponders showed significantly increased PH between baseline and 1 month. At 2 months into therapy, percent recovery was predictive of progression-free survival. Four months prior to progression, there was a significant increase in the standard deviation of percent recovery within the tumor region. DSC perfusion imaging provides valuable information about vascular remodeling during antiangiogenic therapy, which may aid clinicians in identifying patients who will respond at the pretherapy scan and as an early indicator of response to antiangiogenic therapy.

AB - The paradigm for treating patients with glioblastoma multiforme (GBM) is shifting from a purely cytotoxic approach to one that incorporates antiangiogenic agents. These are thought to normalize the tumor vasculature and have shown improved disease management in patients with recurrent disease. How this vascular remodeling evolves during the full course of therapy for patients with newly diagnosed GBM and how it relates to radiographic response and outcome remain unclear. In this study, we examined 35 patients who were newly diagnosed with GBM using dynamic susceptibility contrast (DSC) MRI in order to identify early predictors of radiographic response to antiangiogenic therapy and to evaluate changes in perfusion parameters that may be predictive of progression. After surgical resection, patients received enzastaurin and temozolomide, both concurrent with and adjuvant to radiotherapy. Perfusion parameters, peak height (PH) and percent recovery, were calculated from the dynamic curves to assess vascular density and leakage. Sixmonth radiographic responders showed a significant improvement in percent recovery between baseline and 2 months into therapy, whereas 6-month radiographic nonresponders showed significantly increased PH between baseline and 1 month. At 2 months into therapy, percent recovery was predictive of progression-free survival. Four months prior to progression, there was a significant increase in the standard deviation of percent recovery within the tumor region. DSC perfusion imaging provides valuable information about vascular remodeling during antiangiogenic therapy, which may aid clinicians in identifying patients who will respond at the pretherapy scan and as an early indicator of response to antiangiogenic therapy.

KW - Antiangiogenic therapy

KW - DSC

KW - Enzastaurin

KW - GBM

KW - MRI

KW - Perfusion imaging

UR - http://www.scopus.com/inward/record.url?scp=79951606981&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951606981&partnerID=8YFLogxK

U2 - 10.1093/neuonc/noq143

DO - 10.1093/neuonc/noq143

M3 - Article

C2 - 21036812

AN - SCOPUS:79951606981

VL - 13

SP - 119

EP - 131

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

IS - 1

ER -